Opioid detoxification: From controlled clinical trial to clinical practice

American Journal on Addictions

Volumn 19, Issue 3, 2010, Pages 283-290

  Dijkstra, Boukje A G ^a,b   De Jong, Cor A J ^a,b   Wensing, Michel ^c   Krabbe, Paul F M ^c   Van Der Staak, Cees P F ^b  

^a Novadic Kentron   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NALTREXONE;

ABSTINENCE; ADULT; ARTICLE; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL RESEARCH; COMPARATIVE STUDY; DETOXIFICATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PATIENT COMPLIANCE; SELF REPORT; URINALYSIS;

ADOLESCENT; ADULT; ANESTHESIA, GENERAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; SUBSTANCE ABUSE TREATMENT CENTERS;

EID: 77951127374     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/j.1521-0391.2010.00033.x     Document Type: Article

References (33)

1. Cochrane AL. Effectiveness and Efficiency. Random Reflections on Health Services.
2. Victoria CG, Habicht JP, Bryce J. Evidence-based public health: Moving beyond randomized trials. Am J Public Health. 2004 94 : 400 405.
3. Grossman J, Mackenzie FJ. The randomized controlled trial: Gold standard, or merely standard Perspect Biol Med. 2005 48 : 516 534.
4. Schulz KF. Randomised trials, human nature, and reporting guidelines. Lancet. 1996 348 : 596 598.
5. Schulz KF, Grimes DA. Blinding in randomised trials: Hiding who got what. Lancet. 2002 359 : 696 700.
6. Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995 273 : 408 412.
7. Cartwright ND. Are RCTs the gold standard BioSocieties. 2007 2 : 11 20.
8. Del Boca FK, Darkes J. Enhancing the validity and utility of randomized clinical trials in addictions treatment research. III. Data processing and statistical analysis. Addiction. 2007 102 : 1356 1364. (Pubitemid 47246978)
9. Van Spall HG, Toren A, Kiss A, et al. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: A systematic sampling review. JAMA. 2007 297 : 1233 1240.
10. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ. 1996 312 : 1215 1218.
11. Janevic MR, Janz NK, Dodge JA, et al. The role of choice in health education intervention trials: A review and case study. Soc Sci Med. 2003 56 : 1581 1594.
12. King M, Nazareth I, Lampe F, et al. Conceptual framework and systematic review of the effects of participants' and professionals' preferences in randomised controlled trials. Health Technol Assess. 2005 9 : 1 186, iii iv.
13. Scheeres K, Wensing M, Knoop H, et al. Implementing cognitive behavioral therapy for chronic fatigue syndrome in a mental health center: A benchmarking evaluation. J Consult Clin Psychol. 2008 76 : 163 171.
14. De Maeseneer JM, van Driel ML, Green LA, et al. The need for research in primary care. Lancet. 2003 362 : 1314 1319.
15. Wilkinson LA. Monitoring treatment integrity. School Psychol Int. 2006 27 : 426 438.
16. Dobson KS, Mintz AR. Treatment integrity issues. In : Freeman A, Felgoise SH, Nezu AM, Nezu CM, Reinecke MA, eds. Encyclopedia of Cognitive Behavior Therapy.
17. Gowing LR, Ali R, White J. Opioid antagonists with minimal sedation for opioid withdrawal. Cochrane Database Syst Rev. 2002 : CD002021.
18. Gowing LR, Ali R, White J. Opioid antagonists with minimal sedation for opioid withdrawal. Cochrane Database Syst Rev. 2006 : CD002021.
19. De Jong CAJ, Laheij RJ, Krabbe PFM. General anaesthesia does not improve outcome in opioid antagonist detoxification treatment: A randomized controlled trial. Addiction. 2005 100 : 206 215.
20. Collins ED, Kleber HD, Whittington RA, et al. Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: A randomized trial. JAMA. 2005 294 : 903 913.
21. Gowing LR, Ali R, White J. Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. Cochrane Database Syst Rev. 2006 : CD002022.
22. De Jong CAJ, Roozen HG, van Rossum LG, et al. High abstinence rates in heroin addicts by a new comprehensive treatment approach. Am J Addict. 2007 16 : 124 130.
23. Kokkevi A, Hartgers C. EuropASI. European adaptation of a multidimensional assessment instrument for drug and alcohol dependence. Eur Addict Res. 1995 4 : 208 211.
24. NDM. National Drug Monitor Annual Report 2006.
25. NDM. National Drug Monitor Annual Report 2007.
26. Kaptchuk TJ. The double-blind, randomized, placebo-controlled trial: Gold standard or golden calf J Clin Epidemiol. 2001 54 : 541 549.
27. Bell JR, Young MR, Masterman SC, et al. A pilot study of naltrexone-accelerated detoxification in opioid dependence. Med J Aust. 1999 171 : 26 30.
28. Brewer C, Rezae H, Bailey C. Opioid withdrawal and naltrexone induction in 48-72 hours with minimal drop-out, using a modification of the naltrexone-clonidine technique. Br J Psychiatry. 1988 153 : 340 343.
29. Gerra G, Zaimovic A, Rustichelli P, et al. Rapid opiate detoxification in outpatient treatment: Relationship with naltrexone compliance. J Subst Abuse Treat. 2000 18 : 185 191.
30. Gerra G, Zaimovic A, Giusti F, et al. Lofexidine versus clonidine in rapid opiate detoxification. J Subst Abuse Treat. 2001 21 : 11 17.
31. McCambridge J, Gossop M, Beswick T, et al. In-patient detoxification procedures, treatment retention, and post-treatment opiate use: Comparison of lofexidine + naloxone, lofexidine + placebo, and methadone. Drug Alcohol Depend. 2007 88 : 91 95.
32. O'Connor PG, Carroll KM, Shi JM, et al. Three methods of opioid detoxification in a primary care setting. A randomized trial. Ann Intern Med. 1997 127 : 526 530.
33. Senft RA. Experience with clonidine-naltrexone for rapid opiate detoxification. J Subst Abuse Treat. 1991 8 : 257 259.